Wrinkle
Conditions
Brief summary
The objective of this study is to determine the efficacy and safety of Restylane® Silk microinjections when used in a grid-like injection pattern for the correction of fine lines to the cheeks.
Detailed description
This is a single center, prospective, open-label, clinical trial using micro-injections of Restylane® Silk for correction of mid to low cheek fine lines and wrinkles. Twenty (20) subjects will be enrolled. Each subject will receive Restylane® Silk to a defined area of mid to low cheeks. The injections will be delivered intradermally via multiple 0.02 cc microinjections distributed in a grid array pattern with 1 cm between each injection point. A total surface area of 9-15 cm2 per cheek will be treated depending on the extent of fine lines in each subject. Following completion of injection treatment, manual massage will be applied to the full area to promote even distribution of the product. Each subject will undergo a total of three treatment sessions, one month apart, day 1, week 4, and week 8. The maximum amount of Restylane to be used per treatments session/per cheek is 1.5cc (not to exceed a total of 9 cc) per treated patient. Three dimensional digital photography utilizing the Vectra 3D System (Canfield) will be utilized to document pre-treatment status, sites of injection, and post-treatment effect. Subjects will be followed up at 4 weeks, 8 weeks, post-treatment day 90, and day 180.
Interventions
DEVICERestylane® Silk
Restylane® Silk to a defined area of mid to low cheeks
Sponsors
Goldman, Butterwick, Fitzpatrick and Groff
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Male or female in general good health age 18 or over. 2. Mild to moderate static rhytids involving at least a 9 cm2 area of the mid to low cheeks. 3. Must be willing to give and sign a HIPPA form, photo consent and informed consent form. 4. Must be willing to comply with study dosing and complete the entire course of the study. 5. Female patients will be either of non-childbearing potential defined as: 1. Having no uterus 2. No menses for at least 12 months. Or; (WOCBP) women of childbearing potential must agree to use an effective method of birth control during the course of the study, such as: 1. Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device 2. Intrauterine coil 3. Bilateral tubal ligation 4. Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom) 5. Abstinence (If practicing abstinence must agree to use barrier method described above (4) if becomes sexually active). 6. Vasectomized partner (must agree to use barrier method described above (4) if becomes sexually active with un-vasectomized). 6. Negative urine pregnancy test results Baseline prior to study entry (if applicable)
Exclusion criteria
1. Pregnant, planning pregnancy during the course of the study or breastfeeding 2. Severe static rhytids to the mid to low cheeks 3. Previous use of any form of soft tissue augmentation in the treatment area within the past 12 months 4. Pre-existing medical or dermatologic condition in the treatment area that may affect the treatment or interpretation of treatment effect (at investigator discretion) 5. Presence of tattoo and/or scar in the treatment area that in the investigators opinion would interfere with study assessments 6. Use of oral/topical retinoids within 1 month of Baseline 7. Previous use of botulinum toxins in the treatment area within the past 6 months 8. Previous surgical procedure in the treatment area within the past 12 months 9. Presence or evidence of any conditions that in the opinion of the investigator might impede the subject's ability to give consent or comply with protocol requirements. 10. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study 11. History of non-compliance with clinical research protocols 12. Ablative laser resurfacing to on their face within 12 months 13. Non-ablative laser or light procedures to their face within the past 3 months 14. Known allergy to Restylane® Silk or any of its constituents
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy | Baseline to Day 180 post treatment | Improvement on a validated 9-point Goldman-Fitzpatrick Wrinkle Scale (GFWS) |
Countries
United States
Contacts
Primary ContactIsabella Guiha, CCRC
Outcome results
None listed